Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Aptevo Therapeutics鈥� dense biotech disclosures can feel like reading a second language. Clinical-stage companies such as Aptevo juggle milestone payments, patent filings, and trial data across dozens of forms, so spotting cash-runway updates or understanding toxicology results is challenging. Stock Titan translates every Aptevo Therapeutics SEC filing into plain English, turning 300-page documents into concise briefs backed by AI-powered summaries and real-time alerts.
Whether you need the Aptevo Therapeutics quarterly earnings report 10-Q filing or want Aptevo Therapeutics insider trading Form 4 transactions, our platform surfaces what matters: burn rate trends, dilution risk, and executive stock incentives. Proprietary algorithms flag each Aptevo Therapeutics 8-K material events explained in minutes, while interactive tables track Aptevo Therapeutics executive stock transactions Form 4 as they appear on EDGAR. If you are comparing trial milestones, the Aptevo Therapeutics annual report 10-K simplified section highlights pipeline progress, key risk factors, and intellectual-property status.
Investors typically ask how to read Aptevo Therapeutics鈥� proxy statement executive compensation or where to find Aptevo Therapeutics earnings report filing analysis. Here鈥檚 the streamlined path:
- Instant notice of Aptevo Therapeutics Form 4 insider transactions real-time
- Side-by-side redline of sequential 10-Q footnotes for faster trend analysis
- Natural-language answers for understanding Aptevo Therapeutics SEC documents with AI
Stop skimming PDFs. Our AI technology extracts segment data, clinical updates, and forward-looking statements so you can focus on decisions, not document searches. Aptevo Therapeutics SEC filings explained simply鈥攁lways current, always in context.
Aptevo Therapeutics officer SoYoung Kwon received a grant of 11,500 restricted stock units (RSUs) reported with a transaction date of 08/06/2025. Each RSU converts one-for-one into common stock and the RSUs vest in full on the first anniversary of the grant, creating the potential issuance of 11,500 common shares at no cash price. The reported ownership following the transaction is direct. This disclosure reflects a routine equity-based compensation award to an officer rather than a cash transaction.
Aptevo Therapeutics director Harsanyi Zsolt was granted 7,200 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock and is reported as a direct beneficial interest. The award carries a $0 price and vests in full on the first anniversary of the grant, meaning the holder would receive 7,200 common shares if vesting conditions are met. The reporting form lists a single reporting person and the grant was executed by an attorney-in-fact on behalf of the reporting person.
Aptevo Therapeutics Inc. (APVO) filed a prospectus covering up to 8,250,825 shares reserved for issuance to YA II PN, Ltd. under a Standby Equity Purchase Agreement that commits YA to purchase up to $25.0 million of common stock over a up-to-36-month Commitment Period ending June 16, 2028 (or earlier if fully drawn). YA will purchase Advance Shares at a price equal to 96% of the lowest of three daily VWAPs in the applicable pricing period. The company paid a $25,000 structuring fee and agreed to a 2.00% commitment fee on the $25.0 million Commitment Amount, payable in five quarterly installments.
As of June 30, 2025, 3,224,156 shares were outstanding; if all 8,250,825 shares were issued they would represent approximately 72% of outstanding shares as of July 25, 2025. The Purchase Agreement contains an Ownership Limitation (9.99% beneficial ownership) and previously included an Exchange Cap (151,755 shares) that was removed following stockholder approval on July 24, 2025. The prospectus discloses Nasdaq listing risks, the company鈥檚 1-for-20 reverse split effective May 23, 2025, recent net losses reported for 2024, and an auditor explanatory paragraph regarding going concern uncertainty.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
